Physician profile
Jim Patrick Ellison
NPI 1811251291
$7,778.68
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,776 · 2020: $3,170 · 2021: $524 · 2022: $212 · 2023: $96.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $96.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $96.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $4,807.49 | 2019-2021 | |
| Novo Nordisk INC | $642.03 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $343.17 | 2019-2022 | |
| Glaxosmithkline, LLC. | $324.08 | 2019-2022 | |
| Allergan, INC. | $185.25 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.83 | 2019-2021 | |
| Eisai INC. | $166.19 | 2020-2021 | |
| Amarin Pharma, INC. | $146.77 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $126.78 | 2019-2021 | |
| Astellas Pharma US INC | $123.66 | 2019 | |
| Janssen Pharmaceuticals, INC | $118.07 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $96.48 | 2023 | |
| Abbvie INC. | $56.61 | 2021-2022 | |
| Sk Life Science, INC. | $48.00 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $41.00 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $40.48 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $35.79 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $34.77 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.34 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $30.66 | 2019 | |
| Boston Scientific Corporation | $30.62 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $28.27 | 2019-2020 | |
| Amgen INC. | $27.64 | 2019 | |
| Seqirus USA INC | $16.86 | 2019 | |
| Genentech USA, INC. | $16.83 | 2019 | |
| Upsher-Smith Laboratories LLC | $15.75 | 2019 | |
| Redhill Biopharma INC. | $15.35 | 2020 | |
| Grt US Holding, INC. | $13.44 | 2020 | |
| Global Blood Therapeutics, INC. | $12.87 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.62 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.98 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jim Ellison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.